Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV-1 or HIV-2 infection.
OBJECTIVE
To determine which clinical and immunological features of patients with symptomatic HIV-1 and HIV-2 infection best predict survival in The Gambia.


METHODS
All patients presenting to two hospitals in The Gambia between January 1987 and June 1990 with symptoms or signs suggesting chronic HIV infection were tested for HIV-1 and HIV-2 antibodies. Eighteen HIV-1 and 31 HIV-2-infected patients were recruited to the study, investigated intensively on admission and followed up until the end of 1990. Presenting clinical features, such as Karnofsky score, diagnosis of AIDS according to World Health Organization Bangui or Centers for Disease Control criteria and number of associated infections, together with five immunological measurements, as well as type of HIV infection, were related to length of survival using proportional hazard models fitted to Kaplan-Meier plots of survival times.


RESULTS
Karnofsky score and diagnosis of AIDS were the best clinical predictors of survival. Type of HIV infection or number of associated infections did not predict outcome. The most powerful laboratory predictors were log(e) serum neopterin level, CD4 cell count and log(e) serum beta 2-microglobulin (beta 2M) level. The estimated median survival times (90% confidence interval) of the HIV-1 and HIV-2-infected were six (4-11) and 13 (9-20) months, respectively. These survival times do not differ significantly.


CONCLUSIONS
The Karnofsky score and measurements of serum neopterin or beta 2M, which are easier and cheaper to perform than CD4 counts, may prove to be useful guides to prognosis for HIV infection in Africa.
Medical Research Council Laboratories, Fajara, The Gambia.
H
H
Whittle
A
A
Egboga
J
J
Todd
T
T
Corrah
A
A
Wilkins
E
E
Demba
G
G
Morgan
M
M
Rolfe
N
N
Berry
R
R
Tedder
D000163:Acquired Immunodeficiency Syndrome / Q000175:diagnosis / Q000453:epidemiology*; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis; D001708:Biopterins / Q000031:analogs & derivatives / Q000097:blood; D015496:CD4-Positive T-Lymphocytes; D005260:Female; D005500:Follow-Up Studies; D005714:Gambia / Q000453:epidemiology; D015497:HIV-1; D015498:HIV-2; D006801:Humans; D008297:Male; D019798:Neopterin; D011379:Prognosis; D011446:Prospective Studies; D016019:Survival Analysis; D001613:beta 2-Microglobulin / Q000032:analysis
D000914:Antibodies, Viral; D001613:beta 2-Microglobulin; D001708:Biopterins; D019798:Neopterin